Medicare Bridge program now offers GLP-1 weight-loss drugs with $50 monthly co-pay

CMS's temporary Medicare GLP-1 Bridge program, which launched July 1, 2026, now covers weight-loss drugs like Wegovy and Zepbound for eligible beneficiaries with a $50 monthly co-pay. The program provides temporary coverage for individuals who meet BMI and comorbidity criteria, bridging them until Medicare Part D formulary updates take effect. Practices should ensure front-office staff and billing teams understand the program's eligibility requirements and documentation needed for prior authorization. Confirm patient eligibility and co-pay details before submitting claims for GLP-1 medications under Medicare to avoid denials.